In conjunction with this, research by Yi et al. positions RUNX2 as an epigenetic orchestrator instrumental in facilitating EMT, hence suggesting its utility as a potential prognostic biomarker for breast cancer metastasis [112]. Here, RUNX2 is linked to breast carcinoma.